Investigation on improving immunologic reconstitution insufficiency using DiwuYanggan capsules in AIDS patients

Jing Wen Ke; Yao Chen; En Ze Lei; Ming Zhong Xiao; Wei Ni; Fang Huang; Han Min Li; Hong Lin Jiang; Lian Guo Ruan; Jian Zhong Liu

doi:10.3389/fphar.2024.1485719

Investigation on improving immunologic reconstitution insufficiency using DiwuYanggan capsules in AIDS patients

Front Pharmacol. 2024 Nov 6:15:1485719. doi: 10.3389/fphar.2024.1485719. eCollection 2024.

Authors

Jing Wen Ke^#^{1

2}, Yao Chen^#^{1

2}, En Ze Lei^#³, Ming Zhong Xiao^{1

2

4}, Wei Ni^{1

2

4}, Fang Huang⁵, Han Min Li^{1

2

4}, Hong Lin Jiang⁶, Lian Guo Ruan⁷, Jian Zhong Liu^{1

2

3

4}

Affiliations

¹ Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.
² Hubei Shizhen Laboratory, Wuhan, China.
³ Hubei University of Chinese Medicine, Wuhan, China.
⁴ Hubei Key Laboratory of Liver and Kidney Research and Application of Traditional Chinese Medicine, Wuhan, China.
⁵ Hubei Jiangxia Laboratory, Wuhan, Hubei, China.
⁶ Hubei provincial center for disease control and prevention, Wuhan, China.
⁷ Wuhan Jinyintan Hospital, Wuhan, China.

^# Contributed equally.

Abstract

Background: This study aimed to explore the mechanism of action of DiWuYangGan (DWYG) capsule in improving Immunological non-responder (INR) by analyzing the active ingredients of DWYG.

Methods: The study employed a randomized, controlled, double-blind, single-simulation method. Patients were randomly divided into control and trial groups and treated with the primal highly effective antiretroviral therapy. To demonstrate the effect of DWYG on INR, patients in the control group were administered simulated DWYG, whereas patients in the trial group were administered DWYG capsules (ChiCTR1900024673). The chemical composition of DWYG was analyzed using ultra-performance liquid chromatography-high-resolution mass spectrometry. Potential targets of DWYG in the treatment of INR were identified and predicted using network pharmacology and molecular docking. The molecular mechanisms underlying the effects of DWYG were validated using a peripheral blood monocyte model.

Results: The CD4:CD8 ratio in the trial group was significantly higher than that in the control group (p < 0.01). A total of 210 DWYG compounds were identified and network pharmacology revealed 182 potential therapeutic targets for DWYG and INR. The results of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that the toll-like receptor signaling pathway is one of the key pathways. This study demonstrated that DWYG reduced the expression level of TLR4 and the levels of IL-2, IL-10, and TNF-α, which are important cytokines involved in the immune response.

Conclusion: The efficacy of DWYG in the treatment of INR confirmed the potential practical components of DWYG. Moreover, the results of network pharmacology and experimental validation showed that DWYG could restore the immune function of acquired immune deficiency syndrome patients by inhibiting the expression of TLR4 and related signaling pathways and the overactivation of immune function.

Clinical trial registration: https://www.chictr.org.cn/index.html, identifier ChiCTR1900024673.

Keywords: DiwuYanggan capsule; component analysis; immunological non-responder; network pharmacology; toll-like receptor signaling pathway.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported financially by the National Natural Science Foundation of China (81774280). This work was also supported by Hubei Province “Chutian yingcai Plan” medical and health Talents Project (e weifa [2024] No. 1).